These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 38102622)

  • 1. SARSCoV-2 antibody prevalence and titers in persons living with HIV cared for at a large tertiary reference center in Mexico City.
    Soto-Nava M; Dávila-Conn V; Venancio-Rocha JP; García-Esparza P; Tapia-Trejo D; Hernández-Juan R; Zarza-Sánchez E; Murakami-Ogasawara A; Ávila-Ríos S
    Virol J; 2023 Dec; 20(1):300. PubMed ID: 38102622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
    Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
    Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
    Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
    Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BNT162b2 Elicited an Efficient Humoral Response Against Different Strains of SARS-CoV-2 in People Living with HIV.
    Gidari A; Bastianelli S; Pierucci S; Busti C; Sabbatini S; Schiaroli E; Benedetti S; Gamboni G; Lanzi A; Francisci D
    Curr HIV Res; 2022; 20(4):296-300. PubMed ID: 35909272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV).
    Khan K; Lustig G; Bernstein M; Archary D; Cele S; Karim F; Smith M; Ganga Y; Jule Z; Reedoy K; Miya Y; Mthabela N; Magula NP; Lessells R; de Oliveira T; Gosnell BI; Abdool Karim S; Garrett N; Hanekom W; Bekker LG; Gray G; Blackburn JM; Moosa MS; Sigal A;
    Clin Infect Dis; 2022 Aug; 75(1):e857-e864. PubMed ID: 34893824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
    Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
    Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection.
    Ferrari L; Ruggiero A; Stefani C; Benedetti L; Piermatteo L; Andreassi E; Caldara F; Zace D; Pagliari M; Ceccherini-Silberstein F; Jones C; Iannetta M; Geretti AM;
    Sci Rep; 2024 Apr; 14(1):8337. PubMed ID: 38594459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune response to SARS-CoV-2 variants after immunization with different vaccines in Mexico.
    Garay E; Whelan SPJ; DuBois RM; O'Rourke SM; Salgado-Escobar AE; Muñoz-Medina JE; Arias CF; López S
    Epidemiol Infect; 2024 Feb; 152():e30. PubMed ID: 38312015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
    Corma-Gómez A; Fernández-Fuertes M; García E; Fuentes-López A; Gómez-Ayerbe C; Rivero-Juárez A; Domínguez C; Santos M; Viñuela L; Palacios R; Real LM; Rivero A; Macías J; Pineda JA; García F
    Clin Microbiol Infect; 2022 Nov; 28(11):1492-1498. PubMed ID: 35640840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
    Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM
    J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
    Vanetti C; Stracuzzi M; Crivellaro E; Ciciliano F; Garziano M; Fenizia C; Biasin M; Rubinacci V; Amendola A; Tanzi E; Zuccotti GV; Clerici M; Giacomet V; Trabattoni D
    Front Immunol; 2023; 14():1301766. PubMed ID: 38250079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study).
    Kling KD; Janulis P; Demonbreun AR; Sancilio A; Berzins B; Krueger K; Achenbach C; Price R; Sullivan M; Caputo M; Hockney S; Zembower T; McDade TW; Taiwo B
    Front Immunol; 2022; 13():1048776. PubMed ID: 36700200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study.
    Lombardi A; Butta GM; Donnici L; Bozzi G; Oggioni M; Bono P; Matera M; Consonni D; Ludovisi S; Muscatello A; Ceriotti F; Conti M; Scaglioni S; Gallo G; Scarpa E; Letko M; Abrignani S; Grifantini R; De Francesco R; Gori A; Manganaro L; Bandera A
    Lancet Reg Health Eur; 2022 Feb; 13():100287. PubMed ID: 34961855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
    Di Chiara C; Cantarutti A; Raffaella Petrara M; Bonfante F; Benetti E; Boracchini R; Bosa L; Carmona F; Cosma C; Cotugno N; Le Prevost M; Martini G; Meneghel A; Pagliari M; Palma P; Ruffoni E; Zin A; De Rossi A; Giaquinto C; Donà D; Padoan A
    Vaccine; 2024 Jan; 42(2):263-270. PubMed ID: 38071105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
    Fidler S; Fox J; Tipoe T; Longet S; Tipton T; Abeywickrema M; Adele S; Alagaratnam J; Ali M; Aley PK; Aslam S; Balasubramanian A; Bara A; Bawa T; Brown A; Brown H; Cappuccini F; Davies S; Fowler J; Godfrey L; Goodman AL; Hilario K; Hackstein CP; Mathew M; Mujadidi YF; Packham A; Petersen C; Plested E; Pollock KM; Ramasamy MN; Robinson H; Robinson N; Rongkard P; Sanders H; Serafimova T; Spence N; Waters A; Woods D; Zacharopoulou P; Barnes E; Dunachie S; Goulder P; Klenerman P; Winston A; Hill AVS; Gilbert SC; Carroll M; Pollard AJ; Lambe T; Ogbe A; Frater J
    Clin Infect Dis; 2023 Jan; 76(2):201-209. PubMed ID: 36196614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant.
    Serrano-Conde E; Leyva A; Fuentes A; de Salazar A; Chueca N; Pérez-Castro S; Regueiro B; Rojas A; Mendoza J; Rojas J; García F
    Transbound Emerg Dis; 2022 Sep; 69(5):2649-2655. PubMed ID: 34910373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
    Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
    BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.